Cellectar Biosciences Logo
US15117F8804

Cellectar Biosciences

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +10,24(+150,98%). Der Median liegt bei +10,24(+150,98%).

Kaufen
  7
Halten
  1
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

    FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedicated funds and executive management.» Mehr auf globenewswire.com


  • Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

    FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.» Mehr auf globenewswire.com


  • Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

    Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with iodine-125 (I-125) and actinium-225 (Ac-225) for its clinical studies and future commercial needs.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Cellectar Biosciences einen Umsatz von 0,00 und ein Nettoeinkommen von 6,10 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen6,10 Mio69,47%
EBITDA5,92 Mio46,40%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+188,73 Mio
Anzahl Aktien
46,08 Mio
52 Wochen-Hoch/Tief
+80,63 - +3,72
DividendenNein
Beta
0,52
KGV (PE Ratio)
9,01
KGWV (PEG Ratio)
0,18
KBV (PB Ratio)
+26,80
KUV (PS Ratio)
0,00

Unternehmensprofil

Name
Cellectar Biosciences
CEO
James V. Caruso
SitzFlorham Park, nj
USA
Website
Industrie
Chemikalien
Mitarbeiter11
🍪

Parqet nutzt Cookies.Erfahre Mehr